About This Event

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, visits the Nasdaq MarketSite in Times Square. Immunic’s lead asset, vidofludimus calcium (IMU-838), a once-daily oral small molecule drug, is currently in phase 3 and phase 2 clinical development for relapsing and progressive multiple sclerosis, respectively, and combines neuroprotective, anti-inflammatory, and anti-viral effects with an unparalleled safety and tolerability profile. The company is also developing IMU-856 for celiac disease and other gastrointestinal disorders.

In honor of the occasion, Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, rings the Closing Bell.